Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    ISSN: 1432-0843
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Forty-four adult patients under 60 years of age with acute nonlymphoblastic leukemia were randomized for induction treatment with one of the following three regimens: R 1 = courses of daunorubicin on day 1+ARA-C on days 1–5; R 2 = courses of daunorubicin on days 1 and 2+ARA-C on days 4–8; R 3 = courses of daunorubicin-DNA complex on days 1–2+ ARA-C on days 4–8. Out of 14 patients, 9 went into remission on R 1, 6 out of 14 on R 2, and 8 out of 16 on R 3. The preliminary results suggest that daunorubicin-DNA complex has the same efficacy for inducing remission as daunorubicin alone, if the same time intervals and dosages are used.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    ISSN: 1432-0851
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Of 112 patients (maximum age 70 years) with acute nonlymphocytic leukemia, 62 (55%) went into remission on an induction therapy of cytosine arabinoside and daunorubicin. 20 patients were randomized for maintenance treatment consisting of chemotherapy only and 22 patients for combined chemo-immunotherapy. The chemotherapy consisted in 5-day courses of daunorubicin and cytosine arabinoside and of thioguanine and cytosine arabinoside, alternating every month. The chemo-immunotherapy group also received weekly intracutaneous injections of 109 allogeneic nonirradiated leukemic myeloblasts and 106 BCG organisms (Glaxo) by Heaf gun. The median duration of the first remission was 164 days for the chemotherapy group and 464 days for the chemo-immunotherapy group. The corresponding median times of survival were 344 days for the first group and 734 days for the second group. The difference concerning median duration of survival is statistically significant. Thus immunotherapy seems to prolong survival.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    facet.materialart.
    Unknown
    Ottawa, Ont. : Periodicals Archive Online (PAO)
    Urban history review / Revue d'histoire urbaine. [6]:3 (1978:Feb.) 69 
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    ISSN: 1432-0584
    Keywords: Androgene ; Myeloproliferative Störungen ; Anämie ; Thrombopenie ; Androgens ; Myeloproliferative disorder ; Anemia ; Thrombocytopenia
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Summary In order to study the effect of oxymetholone therapy in advanced myelofibrosis, 11 patients (4 females, 7 males) were given, 3–5 mg per kg body weight, long-term oxymetholone treatment in a prospective multicenter study. Five cases had previously had a diagnosis of polycythemia vera. All patients had anemia initially, 4 leukocytopenia and 10 thrombocytopenia in addition. Hepato-splenomegaly was present in all cases but in varying degree. Five patients required regular blood transfusions before treatment. In 9 of the 15 courses given, there was normalization of the peripheral blood or substantial improvement (better than 3 g hemoglobin/dl or 50×109 platelets/1) after androgens. Significant effects were noted both on hemoglobin values and platelet counts. The need for blood transfusions ceased completely in all 5 cases. When oxymetholone treatment was reduced or interrupted 4 patients relapsed; 2 of them responded to a renewed course. The red cell counts returned to previous polycythemic values in one patient and another died from acute leukemia. The results of this study suggest that androgens might be of value in advanced cases of myelofibrosis with transfusion-requiring anemia or severe thrombocytopenia.
    Notes: Zusammenfassung Die therapeutische Wirksamkeit von Oxymetholon bei fortgeschrittener Osteomyeloflbrose wurde im Rahmen einer prospektiven Studie geprüft. 11 Patienten (4 Frauen, 7 Männer) erhielten 3–5 mg/kg Körpergewicht Oxymetholon. 5 dieser Patienten hatten vorher eine polyzythämische Phase. Alle Patienten hatten bei Beginn des Therapieversuchs eine Anämie, 4 eine Leukopenie und 10 zusätzlich eine Thrombopenie. Eine Hepatosplenomegalie war immer vorhanden. 5 Patienten benötigten vor Behandlung regelmäßig Bluttransfusionen. In 9 von 15 Therapiephasen wurde eine Normalisierung und deutliche Besserung beobachtet. Die Veränderungen des Hämoglobinspiegels und der Plättchenzahl waren signifikant. 4 Patienten verschlechterten sich nach Dosisreduktion oder bei Absetzen von Oxymetholon; 2 davon sprachen erneut an. Bei einem Patienten kehrten die Werte zu den früher bestehenden polyzythämischen Werten zurück. 1 Patient starb durch eine akute Leukämie. Die Ergebnisse der Studie weisen daraufhin, daß Androgene in weit fortgeschrittenen Fällen von Myelofibrose mit transfusionsbedürftiger Anämie oder schwerer Zytopenie von Wert sein könnte.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...